679 related articles for article (PubMed ID: 21601652)
1. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
2. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
3. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
[TBL] [Abstract][Full Text] [Related]
4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
5. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
Modi S; Hughes M; Garrow A; White A
Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083
[TBL] [Abstract][Full Text] [Related]
6. In silico toxicology for the pharmaceutical sciences.
Valerio LG
Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in physicochemical and ADMET profiling in drug discovery.
Wang J; Skolnik S
Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
[TBL] [Abstract][Full Text] [Related]
8. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
9. Knowledge-based chemoinformatic approaches to drug discovery.
Ghose AK; Herbertz T; Salvino JM; Mallamo JP
Drug Discov Today; 2006 Dec; 11(23-24):1107-14. PubMed ID: 17129830
[TBL] [Abstract][Full Text] [Related]
10. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
Palucki M; Higgins JD; Kwong E; Templeton AC
J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
[No Abstract] [Full Text] [Related]
11. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
12. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
13. Strategies for bringing drug delivery tools into discovery.
Kwong E; Higgins J; Templeton AC
Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
[TBL] [Abstract][Full Text] [Related]
14. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
15. Challenges of antibacterial discovery revisited.
Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
[TBL] [Abstract][Full Text] [Related]
16. ADMET--Fifth Annual SMi Conference.
Comer JE
IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
[TBL] [Abstract][Full Text] [Related]
17. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
Luker T; Alcaraz L; Chohan KK; Blomberg N; Brown DS; Butlin RJ; Elebring T; Griffin AM; Guile S; St-Gallay S; Swahn BM; Swallow S; Waring MJ; Wenlock MC; Leeson PD
Bioorg Med Chem Lett; 2011 Oct; 21(19):5673-9. PubMed ID: 21852131
[TBL] [Abstract][Full Text] [Related]
18. Exploratory drug safety: a discovery strategy to reduce attrition in development.
Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
[TBL] [Abstract][Full Text] [Related]
19. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
Trosko JE; Chang CC
Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
[TBL] [Abstract][Full Text] [Related]
20. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]